Abstract
Apoptosis involves mitochondrial steps such as the release of the apoptogenic factor cytochrome c which are effectively blocked by Bcl-2. Although Bcl-2 may have a direct action on the mitochondrial membrane, it also resides and functions on the endoplasmic reticulum (ER), and there is increasing evidence for a role of the ER in apoptosis regulation as well. Here we uncover a hitherto unrecognized, apoptotic crosstalk between the ER and mitochondria that is controlled by Bcl-2. After triggering massive ER dilation due to an inhibition of secretion, the drug brefeldin A (BFA) induces the release of cytochrome c from mitochondria in a caspase-8- and Bid-independent manner. This is followed by caspase-3 activation and DNA/nuclear fragmentation. Surprisingly, cytochrome c release by BFA is not only blocked by wild-type Bcl-2 but also by a Bcl-2 variant that is exclusively targeted to the ER (Bcl-2/cb5). Similar findings were obtained with tunicamycin, an agent interfering with N-linked glycosylations in the secretory system. Thus, apoptotic agents perturbing ER functions induce a novel crosstalk between the ER and mitochondria that can be interrupted by ER-based Bcl-2.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Chloromethyl Ketones / pharmacology
-
Animals
-
Anti-Bacterial Agents / pharmacology
-
Apoptosis / drug effects
-
Apoptosis / physiology*
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / metabolism
-
Biological Transport / drug effects
-
Brefeldin A / metabolism
-
Brefeldin A / pharmacology
-
Caspase 3
-
Caspase 8
-
Caspase 9
-
Caspase Inhibitors
-
Caspases / metabolism
-
Cell Nucleus / metabolism
-
Coumarins / metabolism
-
Cycloheximide / pharmacology
-
Cysteine Proteinase Inhibitors / pharmacology
-
Cytochrome c Group / drug effects
-
Cytochrome c Group / metabolism
-
Endoplasmic Reticulum / drug effects
-
Endoplasmic Reticulum / metabolism*
-
Fibroblasts / drug effects
-
Fibroblasts / metabolism
-
Golgi Apparatus / drug effects
-
Golgi Apparatus / metabolism
-
Golgi Apparatus / ultrastructure
-
Humans
-
Mitochondria / drug effects
-
Mitochondria / metabolism*
-
Mitochondria / ultrastructure
-
Oligopeptides / metabolism
-
Protein Synthesis Inhibitors / pharmacology
-
Proto-Oncogene Proteins c-bcl-2 / genetics
-
Proto-Oncogene Proteins c-bcl-2 / metabolism*
-
Rats
-
Tunicamycin / pharmacology
Substances
-
Amino Acid Chloromethyl Ketones
-
Anti-Bacterial Agents
-
Caspase Inhibitors
-
Coumarins
-
Cysteine Proteinase Inhibitors
-
Cytochrome c Group
-
Oligopeptides
-
Protein Synthesis Inhibitors
-
Proto-Oncogene Proteins c-bcl-2
-
acetyl-aspartyl-glutamyl-valyl-aspartyl-amino-4-methylcoumarin
-
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
-
Tunicamycin
-
Brefeldin A
-
Cycloheximide
-
CASP3 protein, human
-
CASP8 protein, human
-
CASP9 protein, human
-
Casp3 protein, rat
-
Casp8 protein, rat
-
Casp9 protein, rat
-
Caspase 3
-
Caspase 8
-
Caspase 9
-
Caspases